Format

Send to

Choose Destination
Immunol Rev. 2017 Mar;276(1):165-177. doi: 10.1111/imr.12522.

TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Author information

1
Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA.
2
Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA.
3
Department of Neurology, Yale University School of Medicine, New Haven, CT, USA.

Abstract

Cancer immunotherapy utilizing T-cell checkpoint inhibitors has shown tremendous clinical success. Yet, this mode of treatment is effective in only a subset of patients. Unresponsive patients tend to have non-T-cell-inflamed tumors that lack markers associated with the activation of adaptive anti-tumor immune responses. Notably, elimination of cancer cells by T cells is critically dependent on the optimal activity of innate immune cells. Therefore, identifying new targets that regulate innate immune cell function and promote the engagement of adaptive tumoricidal responses is likely to lead to the development of improved therapies against cancer. Here, we review the TAM receptor tyrosine kinases-TYRO3, AXL, and MERTK-as an emerging class of innate immune checkpoints that participate in key steps of anti-tumoral immunity. Namely, TAM-mediated efferocytosis, negative regulation of dendritic cell activity, and dysregulated production of chemokines collectively favor the escape of malignant cells. Hence, disabling TAM signaling may promote engagement of adaptive immunity and complement T-cell checkpoint blockade.

KEYWORDS:

AXL ; MERTK ; TYRO3; innate immune checkpoints

PMID:
28258690
PMCID:
PMC5381815
DOI:
10.1111/imr.12522
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center